Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 18/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 16/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 16/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7971016 | 0.90 | ADRA1A (0.55) | ADRA1AADRA1DADRA1B | |
| SCHEMBL7971028 | 0.90 | ADRA1A (0.55) | ADRA1AADRA1DADRA1B | |
| SCHEMBL7966093 | 0.84 | ADRA1A (0.56) | ADRA1AADRA1DADRA1B | |
| SCHEMBL7966097 | 0.84 | ADRA1A (0.56) | ADRA1AADRA1DADRA1B | |
| SCHEMBL7967692 | 0.84 | ADRA1A (0.71) | ADRA1AADRA1DADRA1B | |
| Hydrochloric Acid SCHEMBL7967690 | 0.83 | ADRA1A (0.70) | ADRA1AADRA1DADRA1B | |
| SCHEMBL7964951 | 0.83 | ADRA1A (0.58) | ADRA1AADRA1DADRA1B | |
| SCHEMBL7971283 | 0.83 | ADRA1A (0.38) | ADRA1AADRA1DADRA1BMCHR1 | |
| Hydrochloric Acid SCHEMBL7964953 | 0.83 | ADRA1A (0.58) | ADRA1AADRA1DADRA1BMCHR1 | |
| Hydrochloric Acid SCHEMBL7964950 | 0.83 | ADRA1A (0.58) | ADRA1AADRA1DADRA1BMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6255315-B1 | BENIGN PROSTATIC HYPERPLASIA | MERCK & CO., INC. | 2001-07-03 | — | — | US | disclosed |
| US-6037354-A | ADMINISTERING PHENYL-SUBSTITUTED THIAZOLIDIN-4-ONE OR OXAZOLIDIN-2-ONE DERIVATIVE TO TREAT BENIGN PROSTATE HYPERPLASIA; SIDE EFFECT REDUCTION | MERCK & CO., INC. (US) | 2000-03-14 | — | — | US | disclosed |